Dr. Clay Siegall is a cancer researcher who built his own company, Seattle Genetics. In his free time he is also a sports enthusiast who likes to put sports-related articles on his official blog. A recent article he posted had to do with the Kansas City Chiefs shipping their quarterback, Alex Smith, off to the Washington NFL team. Now, the Patrick Mahomes era is about to begin with the Chiefs as he will be in his second year in the league and he is ready to play according to the coaches of the team.
In Super Bowl news, Dr. Clay Siegall also posted an article about the Philadelphia Eagles. The coach this team, Doug Pederson, has decided to have former quarterback Brett Farve address his team before the game starts. Pederson has been friends with Farve for many years and he thinks Farve will do a great job getting the team pumped up and ready to play their best game. They will be facing the New England Patriots on February 4th, 2018 with a 3:30 PST kickoff time.
As the president and CEO of his company, Dr. Clay Siegall guides its capital-raising activities in addition to all of his other responsibilities. His company, which went public in 2001, has raised over $675 million from both private and public sources. His company is on the cutting-edge of providing targeted cancer drug therapies in which the drugs his firm develops only kill cells with cancer. He says this is the wave of the future as it’s much safer for patients with far few side effects. Also, it’s much more effective than traditional methods like radiation.
Earlier in his career, Dr. Clay Siegall spent six years working for the National Cancer Institute which is a part of the federal government’s National Institutes of Health. He moved to the Seattle area in 1991 when he got a research position with Bristol-Myers Squib. It was six years after starting work with this pharmaceutical company before he decided to leave and instead co-found Seattle Genetics in Bothell, Washington.
Technology company Tempus, founded in 2015 by Eric Lefkofsky, wants to provide doctors at the University of Chicago data to assist in treatment of patients with breast cancer.Tempus has announced a partnership with the University of Chicago Medicine to provide molecular sequencing and analysis to breast cancer specialists to help them tailor individualized treatment plans for patients. Tempus will analyze data from about 1,000 breast cancer patients to assist in uncovering patterns to predict how patients will respond to treatment.Tempus uses machine learning and genomic sequencing to help with the treatment plans. The goal is for this information to lead to better treatment and patient outcomes.
Dr. Olufunmilayo Olopade, professor of medicine and human genetics and dean for global health at the University of Chicago, said in a statement that specific genetic data could help physicians make better informed and targeted treatment decisions.In recent months, Tempus has entered into partnerships with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the Mayo Clinic, Rush University Medical Center, Penn Medicine and the University of Michigan to use information to battle cancer.In addition to acting as the CEO of Tempus, Eric Lefkofsky is also a founding partner of Lightbank and the co-founder and Chairman of Groupon, Mediaocean, Echo Global Logistics and InnerWorkings.
In 2006 Eric Lefkofsky established the Lefkofsky Family Foundation, a charitable foundation to advance high-impact initiatives that enhance lives in the communities served. Among other positions, Lefkofsky serves as a Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago. He is an adjunct professor at the University of Chicago and author of Accelerated Disruption. He graduated from the University of Michigan in 1991 and received his Juris Doctor from the University of Michigan Law School in 1993.
In a world where everyone is after a solution to the many problems ailing humans, professionals who make bold moves to challenges the problems are viewed as vital assets to the entire world. There are many diseases that have been depriving humans of the peace they desire and most of them are yet to find cure of better ways of controlling their effect. This explains the reason research institutes spend a lot on funding professionals who prove to have the mettle and ability to confront the challenge while pursuing solutions. People like Clay Siegall are the reason we have many drugs able to cure highly dangerous diseases.
He has been conducting research on finding appropriate methods of dealing with cancer and his effort seems to have bore fruits after many years making trials. Clay Siegall works with professionals from various parts of the world to pursue the menace in an effort to offer a solution that will once and for all put to an end the long standing worries about people losing lives due to the lack of an appropriate method of dealing with their problems.
Contribution to Seattle Genetics
As a founder and the CEO of Seattle Genetics, Clay Siegall has invested a lot of time and energy to building the company to a position where it is now able to conduct research and come up with solutions to various problems in the healthcare industry. The company has been investing more into research and looking for solutions to problems that threaten the lives of many.
At Seattle Genetics, Clay B. Siegall has been overseeing all the projects that are meant to offer answers to some diseases. Through this effort, the company was able to release ADCETRIS, which is helping in the fight against cancer. The success of the drug led to its adoption and approval in more than 60 countries and the research to advance its effectiveness further is still in progress. This effort will in few years allow more people to access quality healthcare services that will guarantee putting an end to the many challenges they face while dealing with different diseases.